AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31541008 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level, variable-volume epidural blood patch (EBP)
Number of subjects: 94
Study 29691143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index and Glycemic Load diet (n=34)
Number of subjects: 66
Study 29691143 — intervention group
Group type: COMPARATOR
Intervention: Usual eating plan (n=32)
Number of subjects: 66
Study 26743587 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (containing aspirin 75 mg, simvastatin 20 mg, lisinopril 10 mg and hydrochlorothiazide 12.5 mg)
Number of subjects: 378
Study 26743587 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill
Number of subjects: 378
Study 24267592 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-visual matching paradigm for large numerosities (3:1 ratio)
Number of subjects: 0
Study 24267592 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-visual matching paradigm for small numerosities (2:1 ratio)
Number of subjects: 0
Study 23080351 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 89 mg
Number of subjects: 30
Study 23080351 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 155 mg
Number of subjects: 30
Study 23080351 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 266 mg
Number of subjects: 30
Study 23080351 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl 50 mg
Number of subjects: 30
Study 20206430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg weekly during the second half of the cycle)
Number of subjects: 140
Study 20206430 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (5 mg daily during the second half of the cycle)
Number of subjects: 140
Study 20206430 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 140
Study 20206430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 140
Study 18614930 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 48
Study 18614930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 48
Study 18614930 — intervention group
Group type: COMPARATOR
Intervention: HAART-naive patients
Number of subjects: 48
Study 16023010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy ESWT without local anesthesia (n=45; 3 x 2000 pulses, total energy flux density per shock 0.09 mJ/mm2)
Number of subjects: 86
Study 16023010 — intervention group
Group type: COMPARATOR
Intervention: Low-energy ESWT with local anesthesia (n=41)
Number of subjects: 86
Study 12421062 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate yes-no testing after viewing 5 scenes for 173 ms/picture
Number of subjects: 0
Study 12421062 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing delays of 2 or 6 seconds after viewing 5 scenes
Number of subjects: 0
Study 12421062 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of 10 or 20 pictures
Number of subjects: 0
Study 12421062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-alternative forced-choice recognition test
Number of subjects: 0
Study 12421062 — intervention group
Group type: EXPERIMENTAL
Intervention: Time passage and test interference
Number of subjects: 0
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via MDI alone
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Turbohaler
Number of subjects: 16
Study 10334140 — intervention group
Group type: COMPARATOR
Intervention: Budesonide via MDI spacer
Number of subjects: 16
Study 10334140 — intervention group
Group type: COMPARATOR
Intervention: Budesonide orally
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Nebulizer
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone at 4 mg via MDI spacer
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone at 2 mg via MDI spacer
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide at 4 mg via MDI spacer
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide at 2 mg via MDI spacer
Number of subjects: 16
Study 10334140 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone at 4 mg via MDI spacer
Number of subjects: 16
Study 8951269 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous negative extrathoracic pressure (CNEP, ‐4 to ‐6 cmH2O)
Number of subjects: 244
Study 8951269 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous negative extrathoracic pressure (CNEP)
Number of subjects: 244
Study 8951269 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal intensive care (Control)
Number of subjects: 244
Study 2021655 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 184
Study 2021655 — intervention group
Group type: COMPARATOR
Intervention: N2O-free
Number of subjects: 184
Study 31007049 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-supported recruitment
Number of subjects: 2423
Study 31007049 — intervention group
Group type: COMPARATOR
Intervention: Non-electronic health record recruitment
Number of subjects: 2423
Study 28646169 — intervention group
Group type: EXPERIMENTAL
Intervention: EpxDialysis (digital messaging platform)
Number of subjects: 0
Study 26083771 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine loading (20 g·d⁻¹ for 5 days)
Number of subjects: 19
Study 26083771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23768003 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP ON
Number of subjects: 389
Study 23768003 — intervention group
Group type: COMPARATOR
Intervention: Standard AV settings
Number of subjects: 389
Study 23768003 — intervention group
Group type: COMPARATOR
Intervention: VIP OFF
Number of subjects: 389
Study 21809733 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) and live harp music therapy
Number of subjects: 52
Study 21809733 — intervention group
Group type: COMPARATOR
Intervention: Kangaroo care (KC) alone
Number of subjects: 52
Study 19242062 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutation detection in plasma
Number of subjects: 98
Study 19242062 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testing for NPM1 mutations
Number of subjects: 98
Study 19242062 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutations
Number of subjects: 98
Study 17284748 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (SYN1 + Lactobacillus rhamnosus GG + Bifidobacterium lactis Bb12)
Number of subjects: 80
Study 15462618 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for absolute face recognition judgments
Number of subjects: 0
Study 15462618 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for relative face recognition judgments
Number of subjects: 0
Study 15462618 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for simultaneous mini-lineups
Number of subjects: 0
Study 15462618 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for sequential mini-lineups
Number of subjects: 0
Study 15462618 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of difficulty on CA calibration
Number of subjects: 0
Study 15462618 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative (i.e., new) recognition judgments
Number of subjects: 0
Study 11442858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube (TT) insertion
Number of subjects: 38
Study 11442858 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA) insertion
Number of subjects: 38
Study 9725476 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulations (two new formulations)
Number of subjects: 24
Study 9725476 — intervention group
Group type: COMPARATOR
Intervention: Test capsule
Number of subjects: 24
Study 9725476 — intervention group
Group type: COMPARATOR
Intervention: Test tablet
Number of subjects: 24
Study 9725476 — intervention group
Group type: COMPARATOR
Intervention: Reference capsule
Number of subjects: 24
Study 7976288 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous‐coated rigid femoral component
Number of subjects: 56
Study 7976288 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth, isoelastic femoral component
Number of subjects: 56
Study 7976288 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐operated side)
Number of subjects: 56
Study 2926213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting technique
Number of subjects: 100
Study 2926213 — intervention group
Group type: COMPARATOR
Intervention: Static splinting
Number of subjects: 100
Study 31323779 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (6 mmol nitrate)
Number of subjects: 22
Study 31323779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (6 mmol nitrate)
Number of subjects: 22
Study 31323779 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 22
Study 31323779 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice and Sodium nitrate
Number of subjects: 22
Study 28747642 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + fulvestrant (TF)
Number of subjects: 22
Study 28747642 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (T)
Number of subjects: 22
Study 25387843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injection of vancomycin (1 mg/0.1 ml)
Number of subjects: 60
Study 25387843 — intervention group
Group type: COMPARATOR
Intervention: Intracameral injection of cefuroxime (1 mg/0.1 ml)
Number of subjects: 60
Study 25387843 — intervention group
Group type: COMPARATOR
Intervention: Both groups (vancomycin and cefuroxime)
Number of subjects: 60
Study 23165105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss(®) Collagen (BOC) grafted site
Number of subjects: 9
Study 23165105 — intervention group
Group type: COMPARATOR
Intervention: Control site (empty gap)
Number of subjects: 9
Study 21192751 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated workplace mental health assessment and intervention
Number of subjects: 463
Study 21192751 — intervention group
Group type: COMPARATOR
Intervention: Screening only (Control)
Number of subjects: 463
Study 18642209 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) combined with intravitreal injection of bevacizumab (1.25 mg)
Number of subjects: 23
Study 18642209 — intervention group
Group type: COMPARATOR
Intervention: Standard photodynamic therapy (PDT)
Number of subjects: 23
Study 16564940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 18
Study 16564940 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 18
Study 12705984 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (n=55)
Number of subjects: 98
Study 12705984 — intervention group
Group type: COMPARATOR
Intervention: Saline (n=43)
Number of subjects: 98
Study 10902503 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-oriented interdisciplinary teaching in small groups, including imaging methods (computed tomography, endoscopy, and sonography).
Number of subjects: 300
Study 10902503 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-oriented interdisciplinary teaching in small groups.
Number of subjects: 300
Study 8669166 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week in association with Ursodeoxycholic acid (UDCA) 500 mg/day
Number of subjects: 14
Study 8669166 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 14
Study 1571500 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) enemas
Number of subjects: 40
Study 1571500 — intervention group
Group type: COMPARATOR
Intervention: prednisolone-21-phosphate enemas
Number of subjects: 40
Study 3899970 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine
Number of subjects: 67
Study 3899970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 31550251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Suicide Prevention therapy
Number of subjects: 19
Study 28028714 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert group
Number of subjects: 15
Study 28028714 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled group
Number of subjects: 15
Study 28028714 — intervention group
Group type: COMPARATOR
Intervention: Novice group
Number of subjects: 15
Study 26952224 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg of 0.5% levobupivacaine with 60mg dextrose (Group I)
Number of subjects: 75
Study 26952224 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg of 0.5% levobupivacaine with 80mg dextrose (Group II)
Number of subjects: 75
Study 26952224 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg of 0.5% levobupivacaine with 100mg dextrose (Group III)
Number of subjects: 75
Study 24370543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-resecting pancreaticoduodenectomy (PrPD)
Number of subjects: 130
Study 24370543 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-preserving pancreaticoduodenectomy (PpPD)
Number of subjects: 130
Study 24370543 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (DGE) patients
Number of subjects: 130
Study 24370543 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-DGE patients
Number of subjects: 130
Study 24370543 — intervention group
Group type: EXPERIMENTAL
Intervention: DGE patients
Number of subjects: 130
Study 23099329 — intervention group
Group type: EXPERIMENTAL
Intervention: NDV-3 (30 μg Als3p)
Number of subjects: 40
Study 23099329 — intervention group
Group type: EXPERIMENTAL
Intervention: NDV-3 (300 μg Als3p)
Number of subjects: 40
Study 23099329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 20524773 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow (BM) mononuclear cells prepared using a Sepax device
Number of subjects: 60
Study 20524773 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated systems (the Sepax for processing and the Endosafe device for endotoxin testing)
Number of subjects: 60
Study 17209217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement
Number of subjects: 0
Study 17209217 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 0
Study 15736118 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose (150 mg/d)
Number of subjects: 21
Study 15736118 — intervention group
Group type: EXPERIMENTAL
Intervention: voglibose (0.9 mg/d)
Number of subjects: 21
Study 15736118 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose (50 mg)
Number of subjects: 21
Study 15736118 — intervention group
Group type: EXPERIMENTAL
Intervention: voglibose (0.3 mg)
Number of subjects: 21
Study 9796842 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 400
Study 9796842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 7713815 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion (WE)
Number of subjects: 7
Study 7713815 — intervention group
Group type: COMPARATOR
Intervention: Air exercise (AE)
Number of subjects: 7
Study 7713815 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AE and WE
Number of subjects: 7
Study 2515527 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms daily)
Number of subjects: 64
Study 2515527 — intervention group
Group type: COMPARATOR
Intervention: De‐Nol (5 ml four times a day diluted with 15 ml of water)
Number of subjects: 64
Study 352505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 66
Study 352505 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 66
Study 352505 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin-D
Number of subjects: 66
Study 31165641 — intervention group
Group type: EXPERIMENTAL
Intervention: Maceration dressing
Number of subjects: 56
Study 31165641 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study 30322272 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 206
Study 30322272 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 206
Study 30595326 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Number of subjects: 240
Study 30595326 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Number of subjects: 240
Study 26334785 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygenation strategy with target SpO2 of 88‐92% (n=52)
Number of subjects: 103
Study 26334785 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygenation strategy with target SpO2 of ≥ 96% (n=51)
Number of subjects: 103
Study 23918588 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (3g daily for 12 weeks)
Number of subjects: 10
Study 23918588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22192511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5411
Study 22192511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5411
Study 20210823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural 'self-help' style workbook
Number of subjects: 19
Study 18372721 — intervention group
Group type: EXPERIMENTAL
Intervention: HDBR with TBNP of -15 cmH2O
Number of subjects: 8
Study 18372721 — intervention group
Group type: EXPERIMENTAL
Intervention: HDBR with TBPP of +15 cmH2O
Number of subjects: 8
Study 18372721 — intervention group
Group type: COMPARATOR
Intervention: HDBR
Number of subjects: 8
Study 15781363 — intervention group
Group type: EXPERIMENTAL
Intervention: Artelon TMC Spacer
Number of subjects: 15
Study 15781363 — intervention group
Group type: COMPARATOR
Intervention: Trapezium resection arthroplasty with APL stabilization
Number of subjects: 15
Study 11991875 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with restrictive lung disease
Number of subjects: 10
Study 11991875 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 10
Study 10094168 — intervention group
Group type: EXPERIMENTAL
Intervention: EHRZ (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide)
Number of subjects: 1023
Study 10094168 — intervention group
Group type: COMPARATOR
Intervention: SHRZ (Streptomycin, Isoniazid, Rifampicin, Pyrazinamide)
Number of subjects: 1023
Study 10172365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 20
Study 10172365 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 20
Study 2286438 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam therapy in a cloth tent (Study Group)
Number of subjects: 36
Study 2286438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steam therapy)
Number of subjects: 36
Study 7017244 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (ATG) added to azathioprine and prednisolone
Number of subjects: 50
Study 7017244 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving azathioprine and prednisolone without ATG
Number of subjects: 50
Study 31254388 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening cohort (biennially from age 50 to 69 years)
Number of subjects: 100000
Study 31254388 — intervention group
Group type: COMPARATOR
Intervention: Not screened cohort
Number of subjects: 100000
Study 30421455 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP <120 mmHg
Number of subjects: 995
Study 30421455 — intervention group
Group type: COMPARATOR
Intervention: SBP 120–130 mmHg
Number of subjects: 995
Study 30421455 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 130–140 mmHg
Number of subjects: 995
Study 30421455 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 140–150 mmHg
Number of subjects: 995
Study 30421455 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥150 mmHg
Number of subjects: 995
Study 26343332 — intervention group
Group type: EXPERIMENTAL
Intervention: RED-D (modified brief Cognitive Behavioral Therapy delivered telephonically by a mental health professional)
Number of subjects: 1200
Study 26343332 — intervention group
Group type: COMPARATOR
Intervention: RED plus usual care
Number of subjects: 1200
Study 25208663 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 g of farmed Atlantic salmon fillets per week for 15 weeks
Number of subjects: 42
Study 25208663 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g of salmon oil per week for 15 weeks
Number of subjects: 42
Study 25208663 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 42
Study 22294255 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, cetuximab, and bevacizumab (Arm A)
Number of subjects: 23
Study 22294255 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine, oxaliplatin, and cetuximab (Arm B)
Number of subjects: 23
Study 19963031 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (9 g daily for 12 weeks)
Number of subjects: 0
Study 19963031 — intervention group
Group type: COMPARATOR
Intervention: Control group (hot water)
Number of subjects: 0
Study 17496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 552
Study 17496286 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 552
Study 17496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 552
Study 17496286 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 552
Study 17496286 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI treatment of re-infarction
Number of subjects: 552
Study 17496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 552
Study 17496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 552
Study 17496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional differences in treatment
Number of subjects: 552
Study 15788681 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis-retinoic acid (9-cis-RA)
Number of subjects: 149